Skip to main content
Premium Trial:

Request an Annual Quote

Asuragen to Provide Real-Time PCR Services Based on Exiqon's miRNA Assay Product

Premium

Exiqon and Asuragen said this week that they have signed a service center agreement that allows Asuragen to provide real-time PCR services based on Exiqon's MiRcury LNA Universal RT microRNA PCR products.

Asuragen's genomic services division provides a comprehensive range of nucleic acid-based services from biomarker discovery to development of companion diagnostics, including isolation and preparation from multiple sample types, genomic profiling, miRNA/mRNA expression profiling, assay development and validation, CLIA-based clinical trial testing, bioinformatics, and regulatory services.

Exiqon's LNA-based microRNA real-time PCR profiling combines a Universal RT reaction with locked nucleic acid-enhanced PCR primers, which results in a high degree of sensitivity and specificity for all sample types, the company said. The assay system "holds great promise as a non-invasive way to discover important new biomarkers for a wide range of diseases and biological processes," Exiqon said.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.